Navigation Links
Focused Treatment For Childhood Cancer

A poorly understood type of childhood brain cancer has a unique molecule signature that may point to which therapies could best fight it.// Armed with targeted molecular treatments, doctors may be able to fight the disease without risking the side effects of prolonged and powerful radiation and chemotherapy at an early age.

The latest research is a collaborative effort looking at a type of childhood tumour known as medulloblastoma, the most common childhood tumour of the CNS. The cancer usually strikes between the ages of 5 and 10. Medulloblastomas are highly malignant, and can spread to the spine and other parts of the body. But over the past few decades, refined treatments have increased survival rates until approximately 80 percent of children survive for five to 10 years after diagnosis.

But the therapies aren't perfect. Radiation and chemotherapy for up to a year at such a young age can lead to hearing loss, cataracts and severe learning disabilities that can leave children unable to live independently in later life.

Led by Dr. Scott Pomeroy, an associate professor of neurology at Children's Hospital in Boston, the researchers found that increased activity of Sonic Hedgehog (SHH), a signaling molecule crucial to brain development, is linked to one type of medulloblastoma. "As compared to chemotherapy, which is non-specific and damages all cells … these very focused treatments will only work on those tumors that have that particular molecular pathway active," says Pomeroy.

Recently developed compounds that can block the uncontrolled SHH signaling found in the tumors could potentially be used as a therapy in children with medulloblastoma. Researchers also found that the clinical outcome of an individual child's struggle with medulloblastoma could be accurately predicted by examining the patterns of gene expression in the cancer at the time of diagnosis.
'"/>




Page: 1

Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Inadequate Drug Treatment For Youth
9. FDA Approves New surgery Treatment for Farsightedness
10. Treatment of antibiotics ineffectual in bronchitis
11. Oxygen Treatment may be injurious
Post Your Comments:
(Date:8/8/2008)... 8 /PRNewswire-FirstCall/ -- Hanger Orthopedic,Gro... Moody,s Investors,Service revised its outlook for..."stable." Moody,s also affirmed Hanger,s corporate...ith the outlook change from Moody,s as it reflects...," remarked George McHenry,Hanger,s Chief Financi...
(Date:8/7/2008)...terone may be a key factor in spreading disease am...uld help explain why males in a population are oft...se., , Previous research has linked testosteron...ion. Studies have shown that males, compared to fe...nt for a larger share of disease transmission. How...
(Date:8/7/2008)...Engineering Initiative Marks 12th Year of Summer ...GH, Aug. 7 /PRNewswire/ -- Twenty-four undergradua...ily across southwestern Pennsylvania,and the Pitts...ummer,Internship Program of the Pittsburgh Tissue ...gram is to expose greatly increased numbers of our...
(Date:8/7/2008)... /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE:,...AT study show that,once-daily EPZICOM (abacavir + ...aily Truvada(R) (tenofovir DF + emtricitabine) as ...data were presented today at the 17th,Internationa...s the first large, prospective, long-term, head-to...
Breaking Medicine News(10 mins):Health News:Testosterone key to disease transmission 2Health News:Thirty-seven College Students Participate in Regenerative Medicine Summer Research Program 2Health News:Thirty-seven College Students Participate in Regenerative Medicine Summer Research Program 3Health News:Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients 2Health News:Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients 3Health News:Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients 4Health News:Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients 5
...h study shows that if you happen to posses a certa... double. The gene in question is a specific vari...utosomal recessive disease associated with increas...ts how the body metabolizes iron, which results an...
... supplementation with cacao liquor proanthocyanidi...abetic mice, and may offer human diabetics// signi...etary supplementation with CLPr can dose-dependent...caemia in diabetic obese mice," wrote lead author ...
...e are familiar with terms like ‘grumpy old man’, ‘...say researchers from Colorado University//. Surpri...about life. The research suggests that people bec...older, and it is the young who tend to have a "gla...
...and grapefruits contain chemicals that can keep ar...udy. It suggests that eating at least one orange//... fruits contain the compounds flavanones that redu...s by 20-25 percent during a study on rats, reporte...
Other Medicine News:Health News:Gene Mutation Linked With Risks of Stroke 2Health News:Cocoa Polyphenols may Offer Diabetes Benefits - Study 2
(Date:8/5/2008)...on-Whites New to Antiretroviral Therapy Respond ...EXICO CITY, Aug. 5 /- Initi...ce-daily dosing of Abbott,s (NYSE:,ABT) protease i...rovided,similar results for controlling the virus ...mmune system (increasing CD4 cells) in women compa...
(Date:8/5/2008)... 5 /- Tolerx, Inc., a,biopharmaceutic...t of novel,therapies for the treatment of immune-m...a collaborator, has moved a modified version of TR...to a phase 1 clinical trial,that has begun enrolli...safety and tolerability of both single and multipl...
(Date:8/5/2008)... /PRNewswire/-- Cara Therapeutics, Inc. today,anno...ts second-generation,peripherally acting kappa op...atment of acute and chronic pain. The drug candida...nfusion, and resulted in plasma levels of,CR845 ex...tivity. In,addition, CR845 infusion triggered a qu...
(Date:8/5/2008)...., Aug. 5 /- MicroDose Technologies,I...nical milestone in its,collaboration with Merck & ...ieved, triggering the first payment under the glob...haler (DPI) technology announced in March,2008. Th...Phase I clinical,study of an investigational compo...
Breaking Medicine Technology:Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 2Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 3Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 4Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 5Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 6Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 7Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 8Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 2Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 3Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845 2MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc. 2INCF and Allen Institute for Brain Science collaborate on Brain Atlas service improvement 14608 1INCF and Allen Institute for Brain Science collaborate on Brain Atlas service improvement 14608 2INCF and Allen Institute for Brain Science collaborate on Brain Atlas service improvement 14608 3Research promising for cystic fibrosis 14603 1Research promising for cystic fibrosis 14603 2New Healthcare Study Outlines Strategies to Increase Adoption of Home Health Monitoring Technologies 14598 1New Healthcare Study Outlines Strategies to Increase Adoption of Home Health Monitoring Technologies 14598 2New Healthcare Study Outlines Strategies to Increase Adoption of Home Health Monitoring Technologies 14598 3New study changes conditions for Spanish brown bears 2538 1New study changes conditions for Spanish brown bears 2538 2
...nal reference laboratory and a worldwide leader in...RUP offers an extensive test menu of highly comple...c pathology. Owned by the University of Utah, ARUP...he nation's university teaching hospitals and chil...
...nal reference laboratory and a worldwide leader in...RUP offers an extensive test menu of highly comple...c pathology. Owned by the University of Utah, ARUP...he nation's university teaching hospitals and chil...
...nal reference laboratory and a worldwide leader in...RUP offers an extensive test menu of highly comple...c pathology. Owned by the University of Utah, ARUP...he nation's university teaching hospitals and chil...
...nal reference laboratory and a worldwide leader in...RUP offers an extensive test menu of highly comple...c pathology. Owned by the University of Utah, ARUP...he nation's university teaching hospitals and chil...
Medicine Products: